Natural immune reactivity-associated therapeutic response in patients with metastatic renal cell carcinoma receiving tumor-infiltrating lymphocytes and interleukin-2-based therapy

Journal of Immunotherapy

Volumn 19, Issue 2, 1996, Pages 149-161

  Belldegrun, Arie ^a   Tso, Cho Lea ^a   Kaboo, Randhir ^a   Pang, Shen ^a   Pierce, William ^b   De Kernion, Jean B ^a   Figlin, Robert ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Immunotherapy; Interleukin 2; Renal cell carcinoma; Tumor infiltrating lymphocytes

Indexed keywords

INTERLEUKIN 2;

ADULT; AGED; ARTICLE; CANCER IMMUNOTHERAPY; CANCER SURGERY; CLINICAL ARTICLE; DRUG RESPONSE; FEMALE; HUMAN; IMMUNOPHENOTYPING; KIDNEY CARCINOMA; MALE; METASTASIS; NEPHRECTOMY; PRIORITY JOURNAL; TUMOR ASSOCIATED LEUKOCYTE;

EID: 0030000422     PISSN: 15249557     EISSN: 15374513     Source Type: Journal    
DOI: 10.1097/00002371-199603000-00008     Document Type: Article

References (50)

1. Boring CC, Squires TS, Tong T. Cancer statistics. CA 1991; 41:19-36.
2. Maldazys JD, de Kernion JB. Prognostic factors in metastatic renal carcinoma. J Urol 1986;136:376-9.
3. Belldegrun A, Abi-Ada A, Figlin RA. Renal cell carcinoma: basic biology and current approaches to therapy. Semin On-col 1992;18:96-101.
4. Spiess PJ, Yang JC, Rosenberg SA. In vivo activity of tumor infiltrating lymphocytes expanded in recombinant interleukin-2 mediated potent anti-tumor activity in vivo. J Natl Cancer Inst 1987;79:1067-75.
5. Rosenberg SA, Spiess PJ, Lafreniere R. A new approach to adoptive immunotherapy of cancer with tumor infiltrating lymphocytes. Science 1986;233:1318-21.
6. Whiteside TL, Heo DS, Takagi S, Johnsons JT, Iwatsuki S, Herberman RB. Cytolytic anti-tumor cells in long-term cultures of human tumor-infiltrating lymphocytes in recombinant interleukin-2. Cancer Immunol Immunother 1988;26:1-10.
7. Itoh K, Platsoucas CD, Balch CM. Autologous tumorspecific cytotoxic T lymphocytes in the infiltrate of human metastatic melanomas. J Exp Med 1988;168:1419-41.
8. Rosenberg SA, Packard BS, Aebersold PM, et al. Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma: a preliminary report. N Engl J Med 1988;318:1679-80.
9. Belldegrun A, Pierce W, Kaboo R, et al. Interferon alpha primed tumor infiltrating lymphocytes combined with interleukin 2 and interferon-aipha as a therapy for metastatic renal cell carcinoma. J Urol 1993;150:1384-90.
10. Kurnick JT, Kradin RL, Blumberg R, Schneeberger EE, Boyle LA. Functional characterization of T lymphocytes propagated from human lung carcinomas. Clin Immunol Immunopathol 1986;38:367-80.
11. Aoki Y, Takakuwa K, Kodama S, et al. Use of adoptive transfer of tumor-infiltrating lymphocytes alone or in combination with cisplatin-containing chemotherapy in patients with epithelial ovarian cancer. Cancer Res 1991;51:1934-9.
12. Schendel D, Gansbacher B, Oberneder R, et al. Tumor specific lysis of human renal cells by tumor-infiltrating lymphocytes. J Immunol 1993;151:4209-20.
13. Belldegrun A, Muul LM, Rosenberg SA. Interleukin 2 expanded tumor infiltrating lymphocytes in human renal cell cancer: isolation, characterization, and antitumor activity. Cancer Res 1988;48:206-14.
14. Belldegrun A, Pierce W, Kaboo R, et al. Clinical activity of purified CD8 (+) tumor infiltrating lymphocytes and low dose IL-2 in the treatment of metastatic renal cell carcinoma. Presented at the AUA National Conference, San Francisco, California, May 16, 1994.
15. Belldegrun A, Tso C.-L, Sakata S, et al. Human renal carcinoma line transfected with interleukin-2 and/or interferon α ene(s): implications for live cancer vaccine. J Natl Cancer Inst 1993;85:207-16.
16. Hathorn R, Tso C-L, Kaboo R, et al. In vitro modulation of the invasive and metastatic potentials of human renal cell carcinoma by interleukin-2 and/or interferon-alpha gene transfer. Cancer 1994;74:1904-11.
17. Yao M, Shuin T, Misaki H, Kubota Y. Enhanced expression of c-myc and epidermal growth factor receptor (C-erbB-1) genes in primary human renal cancer. Cancer Res 1988; 48: 6753-7.
18. Gomella LG, Sargent ER, Kasid A. Expression of transforming growth factor α in normal transforming growth factors a and β in renal cell carcinoma. Cancer Res 1989; 49: 6972-5.
19. D’Errico A, Garbisa S, Liotta LA, Castronovo V, Stetler-Stevenson WG, Grigioni WF. Augmentation of type IV collagenase, laminin receptor, and Ki67 antigen associated with human colon, gastric and breast carcinoma progression. Mod Pathol 1991; 4:239-246.
20. Lotz MT, Matory YL, Ettinghausen SE, et al. In-vivo administration of purified human interleukin 2. II. Half life, immunologic effects, and expansion of peripheral lymphoid cells in vivo with recombinant IL-2. J Immunol 1985; 135: 2865-75.
21. Thompson JA, Lee DJ, Kidd P, et al. Influence of dose and duration of infusion of interleukin-2 on toxicity and immunomodulation. J Clin Oncol 1988;6:669-78.
22. Fortis C, Ferrero E, Besana C, et al. Recombinant interleukin-2 and lymphokine-activated killer cells in renal cancer patients: I. Phenotypic and functional analysis of the peripheral blood mononuclear cells. Cancer Immunol Immunother 1990;32:161-6.
23. Sondel PM, Hank JA, Kohler PC, Chen BP, Minkoff DZ, Molenda JA. Destruction of autologous human lymphocytes by interleukin 2-activated cytotoxic cells. J Immunol 1986; 137:502-11.
24. Koo AS, Tso C-L, Shimabukuro T, Peyret C, de Kernion JB, Belldegrun A. Autologous tumor-specific cytotoxicity of tumor infiltrating lymphocytes derived from human renal cell carcinoma. J Immunother 1991;10:347-54.
25. Itoh K, Tilden AB, Balch CM. The role of interleukin-2, and a serum suppressive factor on the induction of activated killer cells cytotoxic for autologous melanoma cells. Cancer Res 1985;45:3173-8.
26. Schwartzentruber DJ, Horn SS, Dadmar ZR, et al. In vitro predictors of therapeutic response in melanoma patients receiving tumor infiltrating lymphocytes and interleukin-2. J Clin Oncol 1994;12:1475-83.
27. Goedegebuure PS, Douville LM, Li H, et al. Adoptive immunotherapy with tumor infiltrating lymphocytes and interleukin-2 in patients with metastatic malignant melanoma and renal cell carcinoma: a pilot study. J Clin Oncol 1995; 13: 1939-2019.
28. Ikarashi H, Fujita K, Takakuwa K, et al. Immunomodulation in patients with epithelial ovarian cancer after adoptive transfer of tumor infiltrating lymphocytes. Cancer Res 1994; 54:190-6.
29. Tso CL, Duckett T, de Kernion JB, Belldegrun AS. Modulation of tumor-infiltrating lymphocytes derived from human renal cell carcinoma by interleukin-4. J Immunother 1992; 12:82-9.
30. Lee TY, Kao AS, Peyret C, Shimabukuro T, de Kernion JB, Belldegrun A. The effects of interleukin-6 on tumorinfiltrating lymphocytes derived from human renal cell cancer. J Urol 1991;145:663-7.
31. Ditonno P, Tso CL, Sakata T, de Kernion JB, Belldegrun A. Regulatory effects of interleukin-7 on renal tumor infiltrating lymphocytes. Urol Res 1992;20:205-10.
32. Applegate KG, Balch CM, Pellis NR. In vitro migration of lymphocytes through collagen matrix: arrested locomotion in TILs. Cancer Res 1990;50:7153-8.
33. Tada T, Ohzeki S, Utsumi K, et al. Transforming growth factor-fS-induced inhibition of T cell function: susceptibility difference in T cells of various phenotypes and functions and its relevance to immunosuppression in the tumor-bearing state. J Immunol 1991;146:1077-82.
34. Whiteside TL, Letessier E, Hirabayashi H, et al. Evidence for local and systemic activation of immune cells by peritumoral injections of interleukin 2 in patients with advanced squamous cells carcinoma of the head and neck. Cancer Res 1993;53:5654-62.
35. Fiorentino DF, Zlotnik A, O’Garra A. IL-10 acts on the antigen presenting cells to inhibit cytokine production by Thl cells. J Immunol 1991;146:3444-51.
36. Chen W-F, Zlotnik A. IL-10: a novel cytotoxic T cell differentiation factor. J Immunol 1991;147:528-34.
37. Maeurer MJ, Martin DM, Castelli C, et al. Host immune response in renal cell cancer: interleukin-4 (IL-4) and IL-10 mRNA are frequently detected in freshly collected tumor infiltrating lymphocytes. Cancer Immunol Immunother 1995;41:111-21.
38. Wang Q, Redovan C, Tubbs R, et al. Selective cytokine gene expression in renal cell carcinoma tumor cells and tumor infiltrating lymphocytes. Int J Cancer 1995;61:780-5.
39. Schwartzentruber DJ, Topalian SL, Mancini M, Rosenberg SA. Specific release granulocyte-macrophage colony stimulating factor, tumor necrosis factor-a and IFN-7 by human tumor infiltrating lymphocytes after autologous tumor stimulation. J Immunol 1991;146:3674-81.
40. Fearon ER, Pardoll DM, Itaya T, et al. Interleukin-2 production by tumor cells bypasses T helper function in the generation of an anti tumor response. Cell 1990;60:397-403.
41. Golumbek PT, Lazenby AJ, Levitsky HI, et al. Treatment of established renal cancer by tumor cells engineered to secrete interleukin-4. Science 1991;254:713-6.
42. Gansbacher B, Bannerji R, Daniels B, Zier K, Cronin K, Gilboa E. Retroviral vector-mediated 7-interferon gene transfer into tumor cells generates potent and long lasting antitumor immunity. Cancer Res 1990;50:7820-5.
43. Colombo MP, Ferrari G, Stoppacciaro A, et al. Granulocyte colony-stimulating factor gene transfer suppresses tumorigenicity of a murine adenocarcinoma in vivo. J Exp Med 1991; 173:889-97.
44. Blankenstein T, Qin ZH, Uberla K, Muller W, Rosen H, Volk H-D, Diamantstein T. Tumor suppression after cell-targeted tumor necrosis factor-alpha gene transfer. J Exp Med 1991;173:1047-52.
45. Blay J-Y, Negrier S, Combaret V, et al. Analysis of changes in serum levels of tumor necrosis factor, IL-2, IL-6 during administration of IL-2: correlation with clinical response to treatment. Bull Cancer (Paris) 1992;79:55-65.
46. Heslop HE, Gottlieb DJ, Bianchi AC, et al. In vivo induction of gamma interferon and tumor necrosis factor by interleukin-2 infusion following intensive chemotherapy and autologous marrow transplantation. Blood 1989;74:1374-80.
47. Shih Y, Konrad MW, Warren MK, et al. Suppression and transient induction of lymphokines in cancer patients after administration of polyethylene glycolate interleukin-2. EurJ Immunol 1992;22:727-33.
48. Loeffler CM, Smyth MJ, Longo DL, et al. Immunoregulation in cancer-bearing hosts: down-regulation of gene expression and cytotoxic function in CD8 + T cells. J Immunol 1992;149:949-56.
49. lck in T-cells infiltrating human renal cell carcinoma. Cancer Res 1993;53:5613-6.
50. Haliotis T, Roder J, Kleun M, Ortoldo J, Fauci AS, Herberman RB. Chediak-Higashi gene in human. I. Impairment of natural killer function. J Exp Med 1980;151:1039-49.